Back to top
more

Inovio Pharmaceuticals (INO)

(Delayed Data from NSDQ)

$10.57 USD

10.57
196,113

+0.45 (4.40%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $10.53 -0.04 (-0.38%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for INO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

Inovio Pharmaceuticals, Inc. [INO]

Reports for Purchase

Showing records 21 - 40 ( 363 total )

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 21

12/15/2021

Company Report

Pages: 5

Positive Progress in VGX-3100 Phase 3 Trials; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 5.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 22

11/10/2021

Company Report

Pages: 6

3Q21 Financial Results Reported; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 12.50

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 23

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for INO

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 24

08/10/2021

Company Report

Pages: 6

COVID-19 Vaccine China Trials Starting; 2Q21 Financials; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 25

06/09/2021

Company Report

Pages: 6

Partnership Expanded for COVID-19 Vaccine Phase 3 Trial; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 26

05/13/2021

Company Report

Pages: 6

Pan-COVID-19 Vaccine Elicits Immunity Against Viral Variants; Reit Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 27

05/11/2021

Company Report

Pages: 6

COVID-19 Vaccine Positive Phase 2 Data; 1Q21 Results; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 28

04/26/2021

Company Report

Pages: 6

U.S. Government Halts COVID-19 Vaccine Phase 3 Funding; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 29

04/16/2021

Company Report

Pages: 6

INO-4800 Elicits Immune Responses to SARS-CoV-2 Variants; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 30

03/02/2021

Company Report

Pages: 6

VGX-3100 Positive Pivotal Top-Line Data; 2020 Results; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 31

03/01/2021

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 10.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 32

02/24/2021

Company Report

Pages: 6

Lassa Fever Vaccine Enters Phase 1b Trial in Africa; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 33

01/07/2021

Company Report

Pages: 6

VGX-3100 Positive Phase 2 Efficacy in Vulvar Dysplasia; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 34

01/05/2021

Company Report

Pages: 6

COVID-19 Vaccine Partnership in Greater China Established; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 35

12/28/2020

Company Report

Pages: 6

INO-4800 COVID-19 DNA Vaccine Phase 1 Data Published; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 36

12/16/2020

Company Report

Pages: 6

dMAb COVID-19 Therapy Collaboration Gets Funding; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 37

12/10/2020

Company Report

Pages: 6

Resolution in 50% of Anal Dysplasia Patients at Six Months; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 38

12/08/2020

Company Report

Pages: 5

Dosing Starts in Phase 2 Trial of DNA COVID-19 Vaccine; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 10.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 39

11/24/2020

Company Report

Pages: 6

INO-3107 Phase 1/2 Trial Dosing Initiation; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party

Company: Inovio Pharmaceuticals, Inc.

Industry: Medical - Biomedical and Genetics

Record: 40

11/23/2020

Company Report

Pages: 7

INO-5401 Favorable 18-Month Brain Cancer Survival Data; Reiterate Neutral

Provider: H.C. Wainwright & Co., Inc.

Analyst: SELVARAJU R

Price: 25.00

Research Provided by a Third Party